With the rapid development of the biotherapeutic industry in Asia, the surge of companies developing biosimilars and the increase in companies outsourcing clinical trials to Asia, now is a critical time to understand, predict and minimize unwanted immunogenicity in biopharmaceutical and biosimilar development.

Immunogenicity poses a risk that should be assessed during drug development, as it possibly compromises drug safety and alters drug characteristics including pharmacokinetics and bioavailability. Immunogenicity assessment strategies combine pre-clinical predictive methods with clinical stage measurement of anti-drug antibodies.

Discover key updates in techniques applied by leading biopharm companies to ensure detection and prediction of immunogenicity throughout the drug development cycle at IBC’s inaugural Immunogenicity for Biopharmaceuticals & Biosimilars Asia.

This event is designed to meet the needs of professionals working in the research, development and commercialization of biopharmaceuticals including:

• Senior Scientists, Lab Head, Principal Scientists, Researchers, Biostatisticians, Directors at Asian biopharm, biosimilar and CROs
• Clinical Development Head, Clinical Research Head of international biopharm looking to outsource/offshore clinical trials to Asia
• CSOs, CEOs, Presidents of domestic biotherapy companies
• Professors, Research Associates, Scientists involved in immunology at domestic academic and research institutes